Caidya, a Raleigh, NC-based global mid-sized CRO, received a $165M growth investment from Rubicon Founders.
The company intends to use the funds to support its next phase of growth, enabling continued organic expansion along with exploration of strategic acquisitions.
Led by CEO Barbara Lopez Kunz, Caidya is a global, mid-sized clinical research organization (CRO) dedicated to advancing healthcare innovation and partnering with biopharma sponsors to bring innovative therapies for unmet medical conditions to our global community. With full-service capabilities and a strategic footprint in 23 countries and regions, its global network provides broad access to diverse patient populations across the Americas, Europe, and APAC.
Its therapeutic and operational expertise spans oncology and hematology, rare and pediatric diseases as well as other fast-growing therapeutic areas where it helps its biopharma partners conduct studies with efficiency and confidence.
FinSMEs
14/01/2025